# cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation

> **NCT04413656** · NA · UNKNOWN · sponsor: **Shanghai Chest Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **OTHER:** ablation
- **OTHER:** surgery

## Key facts

- **NCT ID:** NCT04413656
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-17
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-06-17
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04413656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04413656, "cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04413656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*